The COVID-19 pandemic brought many challenges to each sector of life. The most affected are the health in general and elective services in specific. The postponement of planned surgical procedures is one of the elective services that not only increased the waiting time in the short-term but will strain the healthcare services in the long-run

Background: Breast cancer remains a major global health burden despite therapeutic advances, necessitating further innovations to address persistent challenges like therapeutic resistance, adverse effects, and mortality in subgroups. Emerging technologies offer promising opportunities in this regard through data-driven, precise, and personalized approaches.

The incorporation of patient-reported outcomes (PROs) is essential for assessing whether a cancer treatment enhances overall patient well-being, beyond merely extending survival. This scoping review aimed to identify and analyze the use of PROs in ovarian cancer clinical trials.

Examining BRCA mutations in preoperative breast cancer patients is very important when selecting a surgical procedure. Although there are advantages and disadvantages associated with knowing about the presence of genetic mutations, including for the patient’s family, there are many benefits for the patient. BRCA genetic testing should be recommended for patients who are strongly suspected of being positive for a BRCA mutation. 

Liver masses account for 5 to 6% of pediatric cancer, which includes hepatoblastoma (HBL) along with rare cases of hepatocellular carcinoma (HCC). The most dangerous form of pediatric liver cancer is aggressive HBL, which can be characterized by chemo-resistance and multiple nodules or metastases at diagnosis, all correlating with worse clinical prognosis. Despite intensive studies and a significant improvement in overall outcomes, very little is known about the key molecular pathways which determine the aggressiveness of pediatric liver cancer.